Of drug administration, war and oikos: Mediating cancer with nanomedicines

Nanomedicine

Volumn 10, Issue 21, 2015, Pages 3261-3274

  Loeve, Sacha ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Biomedical ethics; biomilitarism; cancer; ethics of technology; metaphors; molecular Galenics; nano enabled drug delivery systems; philosophy of technology; relational objects

Indexed keywords

NANOCARRIER; ANTINEOPLASTIC AGENT;

CANCER PATIENT; CANCER STEM CELL; CELL COMMUNICATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENVIRONMENT; EPIGENETICS; HUMAN; NANOENABLED DRUG DELIVERY SYSTEM; NANOMEDICINE; NEOPLASM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; THERAPY; DRUG ADMINISTRATION ROUTE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION ROUTES; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84944939646     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.161     Document Type: Review

References (110)

1. Loeve S. La notion d'objet rélationnel dans les nanotechnologies (avec et après Simondon). In: Cahiers Simondon (numéro 6). Barthélémy JH (Ed.). L'Harmattan Paris, France, 47-109 (2015).
2. Schillmeier M. What ELSI/A makes big and small in nanotechnology research. In: Absence in Science, Security and Policy. From Research Agendas to Global Strategy. Rappert B Balmer B (Eds). Palgrave Macmillan, London, UK, 55-77 (2015).
3. Schillmeier M. Caring for social complexity in nanomedicine. Nanomedicine 10(20), 3181-3193 (2015).
4. Rasmussen A. Les enjeux d'une histoire des formes pharmaceutiques: La galénique, l'officine et l'industrie (XIXe-début XXe siècle). Entreprises et histoire 36(2), 12-28 (2004).
5. Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanotech. L. Bus. 5, 135-155 (2008).
6. te Kulve H, Rip A. Economic and societal dimensions of nanotechnology-enabled drug delivery. Expert Opin. Drug Del. 10(5), 611-622 (2013).
7. Vauthier C, Bochot A, Couvreur P. Vers une nouvelle galénique: au chevet du médicament. Biofutur 240, 22-25 (2004).
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development cost. J. Health Econ. 22(2), 151-185 (2003).
9. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010).
10. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet356(9242), 1667-1671 (2000).
11. Downing GJ. Key aspects of health care on the path to personalized medicine. Transl. Res. 154(6), 272-276 (2009).
12. Guchet X. What's in a word The person of personalized (nano)medicine. Nanomedicine 10(20) 3167-3179 (2015).
13. Karatas H, Aktas Y, Gursoy-Ozdemir Y et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci. 29(44), 13761-13769 (2009).
14. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37(1), 48-57 (2010).
15. Boussif O, Lezoualc'h F, Behr JP et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92(16) 7297-7301 (1995).
16. Ryadnov M (Ed.). Bionanodesign: Following Nature's Touch. Royal Society of Chemistry (No. 7), London, UK (2009).
17. Loeve S, Normand M. How to trust a molecule The case of cyclodextrins entering the nanorealm. In: Quantum Engagements. Social Reflections of Nanoscience and Emerging Technologies. Zülsdorf T, Coenen C, Ferrari A et al. (Eds). Akademische Verlagsgesellschaft, Heidelberg, Germany 195-216 (2011).
18. Shenai M. 'Yotta-detection' and 'nano-destruction': emerging innovations in the fight against cancer. Mich. Med. J. 4(1) 35 (2003).
19. Franzen S, Lommel SA. Targeting cancer with 'smart bombs': equipping plant virus nanoparticles for a 'seek and destroy' mission. Nanomedicine 4(5), 575-588 (2009).
20. Prabhu M, Mutnuri S, Dubey SK, Naik MM. One-pot rapid synthesis of face-centered cubic silver nanoparticles using fermented cow urine, a nanoweapon against fungal and bacterial pathogens. J. Bionanosci. 8(4), 265-273 (2014).
21. Sun Q, Wang Q, Rao BK, Jena P. Electronic structure and bonding of Au on a SiO2 cluster: a nanobullet for tumors. Phys. Rev. Lett. 93(18), 186803 (2004).
22. Sarkar D, Spencer JA, Phillips JA et al. Engineered cell homing. Blood 118(25), e184-e191 (2011).
23. Zhang Y. Stealth liposomes: the silent nanobombers. Preclinical Formulation 4, 19-24 (2008).
24. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8(6), 473-480 (2008).
25. Montgomery SL. The Scientific Voice. Guilford Press, NY USA (1996).
26. Nerlich B. Biomilitarism and nanomedicine: evil metaphors for the good of human health http://luthscitech.org/biomilitarism-and-nanomedicine
27. Hodgkin P. Medicine is war: and other medical metaphors. BMJ 291(6511), 1820-1821 (1985).
28. Montgomery SL. Codes and combat in biomedical discourse. Sci. Cult. 2(3), 341-391 (1991).
29. Reisfield GM, Wilson GR. Use of metaphor in the discourse on cancer. J. Clin. Oncol. 22(19), 4024-4027 (2004).
30. Penson RT, Schapira L, Daniels KJ, Chabner BA, Lynch TJ. Cancer as metaphor. Oncologist 9(6), 708-716 (2004).
31. Larson BM, Nerlich B, Wallis P. Metaphors and biorisks: the war on infectious diseases and invasive species. Sci. Commun. 26(3), 243-268 (2005).
32. Mongoven A. The war on disease and the war on terror: a dangerous metaphorical nexus. Camb. Q Health. Ethic 15(04), 403-416 (2006).
33. Camus JTW. Metaphors of cancer in scientific popularization articles in the British press. Discourse Stud. 11(4), 465-495 (2009).
34. Harrington KJ. The use of metaphor in discourse about cancer: a review of the literature. Clin. J. Oncol. Nurs. 16(4) 408-412 (2012).
35. Sontag S. Illness as Metaphor. Farrar, Straus & Giroux, NY USA (1978).
36. Martin E. Toward an anthropology of immunology: the body as nation state. Med. Anthropol. Q. 4(4), 410-426 (1990).
37. Esposito R. Immunitas: The Protection and Negation of Life Polity Press, Cambridge, UK (2011).
38. Faguet G. The Conquest of Cancer: A Distant Goal. Springer Dordrecht, The Netherlands (2014).
39. Annas GJ. Reframing the debate on health care reform by replacing our metaphors. N. Engl. J. Med. 332(11), 744-747 (1995).
40. Olson JS. Making Cancer History: Disease and Discovery at the University of Texas MD Anderson Cancer Center. John Hopkins University Press, MD, USA (2011).
41. Ehrlich P. Address delivered at the Dedication of the Georg-Speyer-Haus. 1906. In: The Collected Papers of Paul Ehrlich. Himmelweit F (Ed.), Pergamon Press, London, UK 53-63 (1960).
42. De Kruif P. Microbe Hunters. Harcourt, Brace and Comp. Inc. NY, USA (1926).
43. Stern F. Paul Ehrlich: the founder of chemotherapy. Angew. Chem. Int. Ed. Engl 43(33), 4254-4261 (2004).
44. Bensaude-Vincent B, Loeve S. Metaphors in nanomedicine: the case of targeted drug delivery. Nanoethics 8(1), 1-17 (2014).
45. Lakoff G, Johnson M. Metaphors We Live By. University of Chicago Press, IL, USA (1980).
46. Nerlich B. From Nautilus to Nanobo(a)ts: the visual construction of nanoscience. AZojono www.azonano.com/article.aspxArticleID=1466
47. Nerlich B. Powered by Imagination: nanobots at the science photo library. Sci. Cult. 17(3), 269-292 (2008).
48. Austin JL. How to Do Things with Words. Clarendon Press Oxford, UK (1962).
49. Galison P. The ontology of the enemy: Norbert Wiener and the cybernetic vision. Crit. Inquiry 21(1), 228-266 (1994).
50. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4(2), 330-342 (2012).
51. Caplan AL, Engelhardt HT, McCartney JJ. Concepts of Health and Disease: Interdisciplinary Perspectives. Addison-Wesley, MA, USA (1981).
52. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J. Control. Release 164(2), 108-114 (2012).
53. Venditto VJ, Szoka FC. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliver. Rev. 65(1) 80-88 (2013).
54. Svenson S. Clinical translation of nanomedicine. Curr. Opin. Solid State Mater. Sci. 16(6), 287-294 (2012).
55. Wang RB, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J. Nanomater. 1, 1-12 (2013).
56. Anselmo AC, Mitragotri S. A review of clinical translation of inorganic nanoparticles. AAPS J. 17(5), 1041-1054 (2015).
57. Lammers T. Smart drug delivery systems: back to the future vs. clinical reality. Int. J. Pharm. 454(1), 527-529 (2013).
58. Narayan VA, Mohwinckel M, Pisano G, Yang M, Manji HK. Beyond magic bullets: true innovation in health care. Nat. Rev. Drug Discov. 12(2), 85-86 (2013).
59. Kostarelas K. Is it time to call a truce in the 'battle against disease' The Guardian (2013). www.theguardian.com/science/small-world/2013/nov/28
60. Gibbs JB, Oliff A. Pharmaceutical research in molecular oncology. Cell 79(2), 193-198 (1994).
61. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675-699 (2007).
62. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17 (3), 330-339 (2011).
63. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
64. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755-768 (2008).
65. Laplane L. Stemness ontology and therapeutic strategies. CAPE Studies in Applied Philosophy Ethics Series 1, 77-99 (2012).
66. Stacey J. Teratologies: A Cultural Study of Cancer. Routledge London, UK (2013).
67. Lorde A. The Cancer Journals. Aunt Lute, CA, USA (1980).
68. Hodgkin P. Medicine is war: and other medical metaphors. BMJ 291(6511), 1820-1821 (1985).
69. Simonton OC, Simonton S, Creighton J. Getting Well Again: A Step-By-Step, Self-Help Guide To Overcoming Cancer For Patients And Their Families. Tarcher, CA, USA (1978).
70. Mitchell GJ, Ferguson-Paré M, Richards CJ. Exploring an alternative metaphor for nursing: Relinquishing military images and language. In: Philosophical and Theoretical Perspectives for Advanced Nursing Practice, Cody WK (Ed.). John & Barlett, MA, USA, 267-278 (2011).
71. Sullivan M. In what sense is contemporary medicine dualistic. Cult. Med. Psychiat. 10(4), 331-350 (1986).
72. Mol A, Law J. Embodied action, enacted bodies: the example of hypoglycaemia. Body Soc. 10(2-3), 42-62 (2004).
73. Levin T, Kissane DW. Psychooncology: the state of its development in 2006. Eur. J. Psychiatry 20(3), 183-197 (2006).
74. Ehrenreich B. Smile! You've got cancer. The Guardian (2010). www.theguardian.com/lifeandstyle/2010/jan/02/cancer
75. Watson M, Haviland J, Greer S, Davidson J, Bliss J. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 354 1331-1336 (1999).
76. Lemon J, Edelman S, Kidman AD. Perceptions of the 'Mind-Cancer' relationship by members of the public, cancer patients and oncologists. J. Psychosoc. Oncol. 21(4), 43-58 (2004).
77. Petticrew M, Bell R, Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. BMJ 325(7372), 1066-1076 (2002).
78. Garssen B. Psychological factors and cancer development: evidence after 30 years of research. Clin. Psychol. Rev. 24(3) 315-338 (2004).
79. Coyne JC, Tennen H. Positive psychology in cancer care: bad science, exaggerated claims, and unproven medicine. Ann. Behav. Med. 39(1), 16-26 (2010).
80. Coyne JC, Pajak TF, Harris J et al. Emotional well-being does not predict survival in head and neck cancer patients. Cancer 110(11), 2568-2575 (2010).
81. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients. Cancer 115(22), 5349-5361 (2009).
82. Nakaya N, Bidstrup PE, Saito-Nakaya K et al. Personality traits and cancer risk and survival based on Finnish and Swedish registry data. Am. J. Epidemiol. 172(4), 377-385 (2010).
83. Ranchor AV, Sanderman R, Coyne JC. Invited commentary: personality as a causal factor in cancer risk and mortality-Time to retire a hypothesis. Am. J. Epidemiol. 172(4) 386-388 (2010).
84. Al-Saleem T. Let's find another metaphor for 'The War on Cancer'. Oncology Times 29(6), 9 (2007).
85. Hauser D, Wasserung R. Do we need to end the 'war' on cancer The Guardian (2015). www.theguardian.com/commentisfree/2015/mar/22
86. McCartney M. The fight is on: military metaphors for cancer may harm patients. BMJ 349, g5155 (2014).
87. Granger K. Having cancer is not a fight or a battle. The Guardian (2014). www.theguardian.com/society/2014/apr/25
88. Rappert B, Balmer B (Eds). Absence in Science, Security and Policy. From Research Agendas to Global Strategy. Palgrave Macmillan, London, UK (2015).
89. Hofmann BM. The technological invention of disease. Med. Hum. 27(1), 10-19 (2001).
90. Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7(6), 606-618 (2012).
91. Gazeau F, Alloyeau D, Pellegrino T. The life-cycle of nanomaterials in the (bio)environment: impact on physical properties and toxicity issue. Presented at: Paris Condensed Matter Conference. Paris, France, 14-29 August 2014.
92. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19(4), 424-436 (2001).
93. Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71(7) 790-792 (1982).
94. Loeve S, Bensaude-Vincent B, Gazeau F. Nanomedicine metaphors: from war to care. Emergence of an oecological approach. Nano Today 8(6), 560-565 (2013).
95. Simondon G. Du mode d' éxistence des objets techniques. Aubier, Paris, France (1958).
96. Lynch I, Dawson KA. Protein-nanoparticle interactions. Nano Today 3(1), 40-47 (2008).
97. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7(12), 779-786 (2012).
98. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41(7), 2780-2799 (2012).
99. Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772-781 (2013).
100. Fadeel B, Feliu N, Vogt C, Abdelmonem AM, Parak WJ. Bridge over troubled waters: understanding the synthetic and biological identities of engineered nanomaterials. Wiley Inter. Rev. Nanomed. Nanobiotechnol. 5(2), 111-129 (2013).
101. Albanese A, Walkey CD, Olsen JB, Guo H, Emili A, Chan WC. Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles. ACS Nano 8(6) 5515-5526 (2014).
102. Gunawan C, Lim M, Marquis CP, Amal R. Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles. J. Mat. Chem. B 2(15) 2060-2083 (2014).
103. Bhattacharya K, Farcal L, Fadeel B. Shifting identities of metal oxide nanoparticles: focus on inflammation. MRS Bulletin 39(11), 970-975 (2014).
104. Docter D, Westmeier D, Markiewicz M, Stolte S, Knauer SK, Stauber RH. The nanoparticle biomolecule corona: lessons learned-challenge accepted Chem. Soc. Rev. 44(17) 6094-6121 (2015).
105. Von Maltzahn G, Park JH, Lin KY et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mat. 10(7), 545-552 (2011).
106. Holme MN, Fedotenko IA, Abegg D et al. Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat. Nanotechnol. 7(8), 536-543 (2012).
107. Silva AK, Kolosnjaj-Tabi J, Bonneau S et al. Magnetic and photoresponsive theranosomes: translating cell-released vesicles into smart nanovectors for cancer therapy. ACS Nano 7(6), 4954-4966 (2013).
108. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6(12) 924-935 (2006).
109. Gatenby RA. A change of strategy in the war on cancer. Nature 459(7246), 508-509 (2009).
110. Gatenby RA, Brown J, Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res. 69(19), 7499-7502 (2009).